Micron‐Size Drug Particles: Common and Novel Micronization Techniques

References

• Robinson J. R. Recent Advantages in Formulation of Poorly Absorbed Drugs. Current Status on Targeted Drug Delivery to the Gastrointestinal Tract. Capsugel Library. 1993; 59–63
   Google Scholar
• Kawashima Y. Nanoparticulate systems for improved drug delivery. Adv. Drug Deliv. Rev. 2001; 47: 1–2
   PubMed Web of Science ®Google Scholar
• Chaumeil J. C. Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find. Exp. Clin. Pharmacol. 1998; 20: 211–215
   PubMed Web of Science ®Google Scholar
• Bisrat M., Nyström C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int. J. Pharm. 1988; 47: 223–231
   Web of Science ®Google Scholar
• Scholz A., Abrahamsson B., Diebold S. M., Kostewicz E., Polentarutti B. I., Ungell A.‐L., Dressmann J. B. Influence of hydrodynamics and particle size on the absorption of felodipine in labradors. Pharm. Res. 2002; 19: 42–47
   PubMed Web of Science ®Google Scholar
• Oh D.‐M., Curl R. L., Yong C.‐S., Amidon G. L. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch. Pharm. Res. 1995; 18: 427–433
   Web of Science ®Google Scholar
• Johnson K. C., Swindell A. C. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 1996; 13: 1795–1798
   PubMed Web of Science ®Google Scholar
• Timsina M. P., Martin G. P., Marriott C., Ganderton D., Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 1994; 101: 1–13
   Web of Science ®Google Scholar
• York P. Powdered raw materials: characterizing batch uniformity. Proc. Respir. Drug Deliv., IV 1994; 83–91
   Google Scholar
• Parrott E. L. J. Swarbrick, J. C. BoylanComminution. Encyclopaedia of Pharmaceutical Technology, . Marcel Decker Inc., New York 1990; Vol. 3: 101–121
   Google Scholar
• Müller R. H., Peters K., Becker R., Kruss B. Nanosuspensions—a novel formulation for the i.v. administration of poorly soluble drugs. Proc. 1st World Meet. APGI/APV 1995; 491–492
   Google Scholar
• Müller R. H., Böhm H. L., Grau M. J. Nanosuspensionen—Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit, 2. Mitteilung: Stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen. Pharm. Ind. 1999; 61: 175–178
   Google Scholar
• Müller R. H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001; 47: 2–19
   Google Scholar
• Müller R. H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size‐reduction technique. Int. J. Pharm. 1998; 160: 229–237
   Web of Science ®Google Scholar
• Müller R. H., Böhm H. L., Grau M. J. Nanosuspensionen—Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit: 1. Herstellung und Eigenschaften. Pharm. Ind. 1999; 61: 74–78
   Google Scholar
• Ostrander K. D., Bosch H. W., Bondanza D. M. An in‐vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 1999; 48: 207–215
   PubMed Web of Science ®Google Scholar
• Liversidge G. G. Formulation of Oral Gastrointestinal Diagnostic X‐ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents. US Patent No. 5628981, 1997
   Google Scholar
• Liversidge G. G., Engers D. A., Roberts M. E., Ruddy S. B., Wong S.‐M., Xu S. Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers. US Patent No. 6068858, 2000
   Google Scholar
• De Castro L., Lee R. Injectable Formulations of Nanoparticulate Naproxen. WO Patent No. 00/09096, 2000
   Google Scholar
• Kondo N., Iwao T., Masuda H., Yamanouchi K., Ishihara Y., Yamada N., Haga T., Ogawa Y., Yokoyama K. Improved oral absorption of a poorly water‐soluble drug, HO‐221, by wet‐bead milling producing particles in submicron region. Chem. Pharm. Bull. 1993; 41: 737–740
   PubMed Web of Science ®Google Scholar
• Roberts R. J., Rowe R. C., York P. The relationship between indentation hardness of organic solids and their molecular structure. J. Mater. Sci. 1994; 29: 2289–2296
   Web of Science ®Google Scholar
• Liversidge G. G., Cundy K. C., Bishop J. F., Czekai D. A. Surface Modified Drug Nanoparticles. US Patent No. 5145684, 1992
   Google Scholar
• Wong S. M. Sugar Base Surfactant for Nanocrystals. US Patent No. 5622938, 1997
   Google Scholar
• Musaeus J. N., Vilstrup P., Winning M. Process of Preparing a Water Dispersible Hydrophobic or Aerophilic Solid. WO Patent No. 9106292, 1991
   Google Scholar
• Wiedmann T. S., Wood R. W., DeCastro L. Aerosols Containing Beclomethazone Nanoparticle Dispersions. US Patent No. 5747001, 1998
   Google Scholar
• De Villiers M. M. Influence of cohesive properties of micronized drug powders on particle size analysis. J. Pharm. Biomed. Anal. 1995; 13: 191–198
   PubMed Web of Science ®Google Scholar
• De Villiers M. M., Tiedt L. R. An analysis of fine grinding and aggregation of poorly soluble drug powders in a vibrating ball mill. Pharmazie 1996; 51: 564–567
   Web of Science ®Google Scholar
• Saleki‐Gerhardt A., Ahlneck C., Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 1994; 101: 237–247
   Web of Science ®Google Scholar
• York P., Ticehurst M. D., Osborn J. C., Roberts R. J., Rowe R. C. Characterization of the surface energetics of milled dl‐propanolol hydrochloride using inverse gas chromatography and molecular modelling. Int. J. Pharm. 1998; 174: 179–186
   Web of Science ®Google Scholar
• Ticehurst M. D., Basford P. A., Dallman C. I., Lukas T. M., Marshall P. V., Nichols G., Smith D. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. Int. J. Pharm. 2000; 193: 247–259
   PubMed Web of Science ®Google Scholar
• Newell H. E., Buckton G., Butler D. A., Thielmann F., Williams D. R. The use of inverse phase gas chromatography to measure the surface energy of crystalline, amorphous, and recently milled lactose. Pharm. Res. 2001; 18: 662–666
   PubMed Web of Science ®Google Scholar
• Grimsey I. M., Feeley J. C., York P. Analysis of the surface energy of pharmaceutical powders by inverse gas chromatography. J. Pharm. Sci. 2002; 91: 571–583
   PubMed Web of Science ®Google Scholar
• Mackin L., Sartnurak S., Thomas I., Moore S. The impact of low levels of amorphous material (< 5%) on the blending characteristics of a direct compression formulation. Int. J. Pharm. 2002; 231: 213–226
   PubMed Web of Science ®Google Scholar
• Elamin A. A., Sebhatu T., Ahlneck C. The use of amorphous model substances to study mechanically activated materials in the solid state. Int. J. Pharm. 1995; 119: 25–36
   Web of Science ®Google Scholar
• Steckel H., Rasenack N., Müller B. W. In vitro characterization of jet‐milled and in‐situ‐micronized fluticasone‐17‐propionate. Int. J. Pharm. 2003; 258: 65–75
   PubMed Web of Science ®Google Scholar
• Briggner L.‐E., Buckton G., Bystrom K., Darcy P. The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders. Int. J. Pharm. 1994; 105: 125–135
   Web of Science ®Google Scholar
• Buckton G. Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv. Drug Deliv. Rev. 1997; 26: 17–27
   PubMed Web of Science ®Google Scholar
• Ward G. H., Schultz R. K. Process‐induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 1995; 12: 773–779
   PubMed Web of Science ®Google Scholar
• Buckton G., Choularton A., Beezer A. E., Chatham S. M. The effect of the comminution technique on the surface energy of a powder. Int. J. Pharm. 1988; 47: 121–128
   Web of Science ®Google Scholar
• Mestl G., Herzog B., Schlögl R., Knözinger H. Mechanically activated MoO3. 1. Particle size, crystallinity, and morphology. Langmuir 1995; 11: 3027–3034
   Web of Science ®Google Scholar
• Mestl G., Verbruggen N. F.D., Knözinger H. Mechanically activated MoO3. 2. Characterization of defect structures. Langmuir 1995; 11: 3035–3041
   Google Scholar
• Florence S. T., Salole E. G. Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and estradiol. J. Pharm. Pharmacol. 1976; 28: 637–642
   PubMed Web of Science ®Google Scholar
• Elamin A. A., Ahlneck C., Alderborn G., Nyström C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm. 1994; 111: 159–170
   Web of Science ®Google Scholar
• Mosharraf M., Sebhatu T., Nyström C. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int. J. Pharm. 1999; 177: 29–51
   PubMed Web of Science ®Google Scholar
• Yamamoto K., Nakano M., Arita T., Nakai Y. Dissolution rate and bioavailabity of griseofulvin from a ground mixture with microcrystalline cellulose. J. Pharmacokinet. Biopharm. 1974; 2: 487
   PubMedGoogle Scholar
• Yamamoto K., Nakano M., Arita T., Takayama Y., Nakai Y. Dissolution behaviour of phenytoin from a ground mixture with microcrystalline cellulose. J. Pharm. Sci. 1976; 65: 1484–1488
   PubMed Web of Science ®Google Scholar
• Feeley J. C., York P., Sumby B. S., Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. Int. J. Pharm. 1998; 172: 89–96
   Web of Science ®Google Scholar
• Joshi V., Dwivedi S., Ward G. H. Increase in the specific surface area of budesonide during storage postmicronization. Pharm. Res. 2002; 19: 7–12
   PubMedGoogle Scholar
• Waltersson J. O., Lundgren P. The effect of mechanical comminution on drug stability. Acta Pharm. Suec. 1985; 22: 291–300
   PubMedGoogle Scholar
• Kitamura S., Miyamae A., Koda S., Morimoto Y. Effect of grinding on the solid‐state stability of cefixime trihydrate. Int. J. Pharm. 1989; 56: 125–134
   Google Scholar
• Horn D., Rieger J. Organische Nanopartikel in wässriger Phase—Theorie, Experiment und Anwendung. Angew. Chem. 2001; 113: 4460–4492
   Google Scholar
• Allemann E., Gurny R., Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting‐out process: influence of process parameters on particle size. Int. J. Pharm. 1992; 87: 247–253
   Web of Science ®Google Scholar
• Ruch F., Matijevic E. Preparation of micrometer size budesonide particles by precipitation. J. Colloid Interface Sci. 2000; 229: 207–211
   PubMed Web of Science ®Google Scholar
• Reetz M. T., Helbig W. Size‐selective synthesis of nanostructured transition metal clusters. J. Am. Chem. Soc. 1994; 116: 7401–7402
   Web of Science ®Google Scholar
• Becker J. A., Schäfer R., Festag R., Ruland W., Wendorff J. H., Pebler J., Quaiser S. A., Helbig W., Reetz M. T. Electrochemical growth of superparamagnetic cobalt clusters. J. Chem. Phys. 1995; 103: 2520–2527
   Web of Science ®Google Scholar
• Reetz M. T., Quaiser S. A. Eine neue Methode zur Herstellung nanostrukturierter Metallcluster. Angew. Chem. 1995; 107: 2461–2463
   Google Scholar
• Becker J. A., Schäfer R., Festag J. R., Wendorff J. H., Hensel F., Pebler J., Quaiser S. A., Helbig W., Reetz M. T. Magnetic properties of cobalt‐cluster dispersions generated in an electrochemical cell. Surf. Rev. Lett. 1996; 3: 1121–1126
   Google Scholar
• Privman V., Goia D. V., Park J., Matijevic E. Mechanism of formation of monodispersed colloids by aggregation of nanosize precursors. J. Colloid Interface Sci. 1999; 213: 36–45
   PubMed Web of Science ®Google Scholar
• DAB 9. Deutsches Arzneibuch (German Pharmacopoeia)9th Ed. 1986, Deutscher Apothekerverlag Stuttgart, Govi Verlag GmbH Frankfurt
   Google Scholar
• Corrigan O. I., Holohan E. M., Sabra K. Amorphous forms of thiazide diuretics prepared by spray‐drying. Int. J. Pharm. 1984; 18: 195–200
   Google Scholar
• Sebhatu T., Angberg M., Ahlneck C. Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int. J. Pharm. 1994; 104: 135–144
   Web of Science ®Google Scholar
• Vidgrén M. T., Vidgrén P. A., Paronen T. P. Comparison of physical and inhalation properties of spray‐dried and mechanically micronized disodium cromoglycate. Int. J. Pharm. 1987; 35: 139–144
   Web of Science ®Google Scholar
• Chawla A., Taylor K. M.G., Newton J. M., Johnson M. C.R. Production of spray‐dried salbutamol sulphate for use in dry powder aerosol formulations. Int. J. Pharm. 1994; 108: 233–240
   Web of Science ®Google Scholar
• Chew N. Y.K., Bagster D. F., Chan H.‐K. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int. J. Pharm. 2000; 206: 75–83
   PubMed Web of Science ®Google Scholar
• Loth H., Hemgesberg E. Properties and dissolution of drugs micronized by crystallization from supercritical gases. Int. J. Pharm. 1986; 32: 265–276
   Web of Science ®Google Scholar
• York P. Strategies for particle design using supercritical fluid technologies. PSTT 1999; 2(11)430–440
   PubMedGoogle Scholar
• Kerc J., Srcic S., Knez Z., Sencar‐Bozic P. Micronization of drugs using supercritical carbon dioxide. Int. J. Pharm. 1999; 182: 33–39
   PubMed Web of Science ®Google Scholar
• Steckel H., Thies J., Müller B. W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm. 1997; 152: 99–110
   Web of Science ®Google Scholar
• Moshashaée S., Bisrat M., Forbes R. T., Nyquist H., York P. Supercritical fluid processing of proteins I: Lysozyme precipitation from organic solution. Eur. J. Pharm. Sci. 2000; 11: 239–245
   PubMed Web of Science ®Google Scholar
• Matson D. W., Fulton J. L., Peterson R. C., Smith R. D. Rapid expansion of supercritical fluid solutions: solute formulation of powders, thin films and fibers. Ind. Eng. Chem. Res. 1987; 26: 2298–2306
   Web of Science ®Google Scholar
• Türk M., Hils P., Helfgen B., Schaber K., Martin H.‐J., Wahl M. A. Micronization of pharmaceutical substances by the Rapid Expansion of Supercritical Solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J. Supercrit. Fluids 2002; 22: 75–84
   Web of Science ®Google Scholar
• Tom J. W., Debenedetti P. G., Jerome R. Precipitation of poly (L‐lactic acid) and composite poly (L‐lactic acid)‐pyrene particles by rapid expansion of supercritical solution. J. Supercrit. Fluids 1994; 7: 9–29
   Web of Science ®Google Scholar
• Lele A. K., Shine A. D. Effect of RESS dynamics on polymer morphology. Ind. Eng. Chem. Res. 1994; 33: 1476–1485
   Web of Science ®Google Scholar
• Müller B. W., Fischer W. Verfahren zur Herstellung einer mindestens einen Wirkstoff und einen Träger umfassenden Zubereitung. German Patent Application DE 3744329A1, 1989
   Google Scholar
• Gallagher P. M., Coffey M. P., Krukonis V. J., Klasutis N. K. P. Johnston, J. M.L. PenningerGas antisolvent recrystallization: new process to recrystallize compounds insoluble in supercritical fluids. Supercritical Science and Technology, . ACS Symposium Series, Washington, DC 1989; Vol. 406: 334–354
   Google Scholar
• Dixon D. J., Johnston K. P., Bodmeier R. A. Polymeric materials formed by precipitation with a compressed fluid antisolvent. AIChE J. 1993; 39(1)127–139
   Web of Science ®Google Scholar
• Yeo S.‐D., Debenedetti P. G., Radosz M., Schmidt H.‐W. Supercritical antisolvent process for substituted para‐linked aromatic polyamides: phase equilibrium and morphology study. Macromolecules 1993; 26: 6207–6210
   Web of Science ®Google Scholar
• Tachibana T., Nakamura A. A method for preparing an aqueous colloidal dispersion of organic materials by using water‐soluble polymers: dispersion of beta‐carotine by polyvinylpyrrolidone. Kolloid‐Z. Polym. 1965; 203: 130–133
   Web of Science ®Google Scholar
• List M., Sucker H. Pharmaceutical colloidal hydrosols for injection. GB Patent No. 2200048A, 1988
   Google Scholar
• Gaßmann P., Sucker H. Improvements in Pharmaceutical Compositions. WO Patent No. 92/18105, 1992
   Google Scholar
• Gaßmann P., List M., Schweitzer A., Sucker H. Hydrosols—alternatives for the parenteral application of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 1994; 40: 64–72
   Web of Science ®Google Scholar
• Gust R., Bernhardt G., Spruß T., Krauser R., Koch M., Schönenberger H., Bauer K. H., Schertl S., Lu Z. Development of a parenterally administrable hydrosol preparation of the “third generation platinum complex”: part 1. Preparation and studies on the stability and antitumor activity. Arch. Pharm. (Weinh.) 1995; 328: 645–653
   PubMedGoogle Scholar
• Horn D., Schmidt H. W., Ditter W., Hartmann H., Lueddecker E., Schmieder K. Verfahren zur Herstellung von feinverteilten, pulverförmigen Carotenoid‐bzw. Retinoidpräparaten. EP Patent No. 0065193A2, 1982
   Google Scholar
• Horn D. Preparation and characterisation of microdisperse bioavailable carotenoid hydrosols. Angew. Makromol. Chem. 1989; 166/167: 139–153
   Google Scholar
• Auweter H., Bohn H., Haberkorn H., Horn D., Lüddecke E., Rauschenberger V. Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotenoid‐Zubereitungen und die Verwendung der neuen Carotenoid‐Zubereitungen. DE Patent No. 19637517A1, 1996
   Google Scholar
• Rouchotas C., Cassidy O. E., Rowley G. Comparison of surface modification and solid dispersion techniques for drug dissolution. Int. J. Pharm. 2000; 195: 1–6
   PubMed Web of Science ®Google Scholar
• Pozarnsky G. A., Matijevic E. Preparation of monodisperse colloids of biologically active compounds: 1. Naproxen. Colloids Surf., A Physicochem. Eng. Asp. 1997; 125: 47–52
   Google Scholar
• Cathrein E., Stein H., Stoller H. J., Viardot K. Process for the Production of Carotenoid Preparations. EP Patent No. 0410236, 1991
   Google Scholar
• Rasenack N., Müller B. W. Dissolution rate enhancement by in‐situ‐micronization of poorly water‐soluble drugs. Pharm. Res. 2002; 19: 1896–1902
   Google Scholar
• Rasenack N., Steckel H., Müller B. W. Micronization of anti‐inflammatory drugs for pulmonary delivery by a controlled crystallization process. J. Pharm. Sci. 2003; 92: 35–44
   PubMed Web of Science ®Google Scholar
• Rasenack N., Hartenhauer H., Müller B. W. Microcrystals for dissolution rate enhancement of poorly water‐soluble drugs. Int. J. Pharm. 2003; 254: 137–145
   PubMed Web of Science ®Google Scholar
• Steckel H., Rasenack N., Müller B. W. In‐situ‐micronization of disodium cromoglycate for pulmonary delivery. Eur. J. Pharm. Biopharm. 2003; 55: 173–180
   PubMed Web of Science ®Google Scholar
• Chang S. A., Gray D. G. The surface tension of aqueous hydroxypropyl cellulose solutions. J. Colloid Interface Sci. 1978; 67: 225–265
   Google Scholar
• Daniels R., Barta A. Pharmacopoeial cellulose ethers as oil‐in‐water emulsifiers. I. Interfacial properties. Eur. J. Pharm. Biopharm. 1994; 40: 128–133
   Google Scholar
• Rasenack N., Steckel H., Müller B. W. In‐situ‐micronization of drugs: improvement of pulmonary dosage forms. Proc. Drug Deliv. Lungs XIII 2002; 75–78
   Google Scholar
• Chen X., Young T. J., Sarkari M., Williams R. O., III, Johnston K. P. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002; 242: 3–14
   PubMed Web of Science ®Google Scholar
• Sarkari M., Brown J., Chen X., Swinnea S., Williams R. O., III, Johnston K. P. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 2002; 243: 17–31
   PubMed Web of Science ®Google Scholar
• Rogers T. L., Hu J., Yu Z., Johnston K. P., Williams R. O., III. A novel particle engineering technology: Spray freezing into liquid. Int. J. Pharm. 2002; 242: 93–100
   PubMed Web of Science ®Google Scholar
• Yu Z., Rogers T. L., Hu J., Johnston K. P., Williams R. O., III. Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid. Eur. J. Pharm. Biopharm. 2002; 54: 221–228
   PubMed Web of Science ®Google Scholar